A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

Start Date01 Jan 2030

Sponsor / Collaborator

Lisata Therapeutics, Inc.

NCT07365306

/ Not yet recruitingPhase 2IIT

A Phase 2 Study of Epcoritamab-R-GemOx With Consolidative ASCT and Additional Epcoritamab in Relapsed/Refractory Transplant-Eligible DLBCL

This phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before autologous stem cell transplant in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Epcoritamab is a so-called bispecific antibody, a molecule that can bind simultaneously to two different receptors (proteins present on the cell surface). Epcoritamab binds to a receptor called CD3 with one part of the antibody and to a receptor called CD20 with another part of the antibody. CD3 is expressed on T cells, which are important cells of the immune system that help the body fight cancers and infections. CD20 is expressed on the surface of DLBCL cells. By simultaneous binding to CD3 and CD20, epcoritamab brings T cells and DLBCL cells close together and activates the T cells to kill the lymphoma cells. Rituximab is a so-called monoclonal antibody, a molecule that binds to a single receptor. Like epcoritamab, rituximab binds to CD20. After binding to CD20, rituximab activates the immune system to kill the lymphoma cell through several different mechanisms. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Giving epcoritamab-R-GemOx as therapy before an autologous stem cell transplant may help kill cancer cells in the body and help make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.

Start Date30 Dec 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07275216

/ Not yet recruitingPhase 2IIT

Phase 2 Study of Pembrolizumab With Chemotherapy in Frail Patients With Newly Diagnosed Classical Hodgkin Lymphoma

This phase II trial tests how well pembrolizumab in addition to chemotherapy (gemcitabine, brentuximab vedotin, and dacarbazine) works in treating frail patients with newly diagnosed Hodgkin lymphoma who aren't candidates for standard anthracycline-based treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Dacarbazine is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells and slow down or stop cancer growth. Pembrolizumab in combination chemotherapy may be a safe and effective alternative treatment option for frail patients with Hodgkin lymphoma who can't receive standard anthracycline-based treatment.

Start Date01 Jul 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Gemcitabine Hydrochloride

100 Translational Medicine associated with Gemcitabine Hydrochloride

100 Patents (Medical) associated with Gemcitabine Hydrochloride

12,304

Literatures (Medical) associated with Gemcitabine Hydrochloride

01 Jan 2026·Gan to kagaku ryoho. Cancer & chemotherapy

[Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].

Article

Author: Inoue, Keiji ; Shigehisa, Ryu ; Fukata, Satoshi

Bladder cancer is a common malignancy in the elderly, with approximately 75% of cases diagnosed as non-muscle-invasive bladder cancer(NMIBC).Although transurethral resection of bladder tumor(TURBT)is the standard initial treatment, recurrence rates remain high, and intravesical Bacillus Calmette-Guérin(BCG)instillation has long been used as an adjuvant therapy.However, about 30% of patients develop BCG-unresponsive disease despite adequate BCG administration.Radical cystectomy is recommended in such cases, but its invasiveness and impact on quality of life(QOL)often make it impractical in real-world settings.Thus, the development of novel bladder-preserving treatments is urgently needed.In recent years, diverse approaches including immune checkpoint inhibitors(ICI), gene therapy, drug delivery systems(DDS), and oncolytic virus-based therapies have been actively investigated, with numerous clinical trials ongoing worldwide.Importantly, pembrolizumab, nadofaragene firadenovec, and N-803 in combination with BCG have received FDA approval, representing major advances in the management of BCG-unresponsive NMIBC.In addition, promising agents such as TAR-200, cretostimogene grenadenorepvec, and detalimogene voraplasmid are under clinical evaluation.These advances indicate the potential for novel strategies that enable bladder preservation while achieving tumor control.Future challenges include validation of long-term outcomes, establishment of evidence through randomized controlled trials, and regulatory approval and reimbursement in Japan.Expansion of therapeutic options is expected to improve both prognosis and QOL in this high-risk population.

01 Jan 2026·MOLECULAR BIOTECHNOLOGY

Exploring the Effects of Opioid-Related Drugs on the Clinical Outcome of Prostate Cancer Patients Via Integrated Bioinformatics Analysis

Article

Author: Zhang, Yunxuan ; Cao, Qi ; Miao, Qi ; Liu, Yuenan ; Zhang, Xiaoping ; Chen, Kailei

Opioids are the primary regimens for perioperative analgesia with controversial effects on oncological survival. The underlying mechanism remains unexplored. This study developed survival-related gene co-expression networks based on RNA-seq and clinical characteristics from TCGA cohort. Two survival-related networks were identified, and drug-induced transcriptional profiles were predicted. Immune cell infiltration algorithm, least absolute shrinkage and selection operator (LASSO) regression, and cox proportional models were executed to explore the correlation between opioid-related drugs and prostate cancer patient prognosis. The opioid receptor agonists, represented by tramadol, were evidenced for anti-survival effects on prostate cancer by facilitating the DNA replication and cell cycle, and immune cell infiltration. Conversely, opioid receptor antagonists showed pro-survival effects. A novel prognostic model containing CNIH2, MCCC1, and Gleason scores was established and validated in two independent cohorts. This study revealed opioids' effect on prostate cancer progression, and provided a novel model to predict these regulations in clinical outcomes.

01 Dec 2025·ADVANCED MATERIALS

Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy

Article

Author: Jon Ostolaza-Paraiso ; Dhruv Menon ; João Conde ; Sergio Mercado ; Jhenifer Oliveira ; Xu Chen ; Bárbara B. Mendes ; David Fairen-Jimenez ; João Conniot ; Francesca Melle

Abstract:

Despite improvements in cancer survival rates, metastatic and surgery‐resistant cancers, such as pancreatic cancer, remain challenging, with poor prognoses and limited treatment options. Enhancing drug bioavailability in tumors, while minimizing off‐target effects, is crucial. Metal–organic frameworks (MOFs) have emerged as promising drug delivery vehicles owing to their high loading capacity, biocompatibility, and functional tunability. However, the vast chemical diversity of MOFs complicates the rational design of biocompatible materials. This study employed machine learning and molecular simulations to identify MOFs suitable for encapsulating gemcitabine, paclitaxel, and SN‐38, and identified PCN‐222 as an optimal candidate. Following drug loading, MOF formulations are improved for colloidal stability and biocompatibility. In vitro studies on pancreatic cancer cell lines have shown high biocompatibility, cellular internalization, and delayed drug release. Long‐term stability tests demonstrated a consistent performance over 12 months. In vivo studies in pancreatic tumor‐bearing mice revealed that paclitaxel‐loaded PCN‐222, particularly with a hydrogel for local administration, significantly reduced metastatic spread and tumor growth compared to the free drug. These findings underscore the potential of PCN‐222 as an effective drug delivery system for the treatment of hard‐to‐treat cancers.

848

News (Medical) associated with Gemcitabine Hydrochloride

28 Jan 2026

·www.globenewswire.com

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical DataMOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting has been accepted. The meeting will be held February 4–8, 2026 in Savannah, Georgia. Researchers including Christopher Laing, MD of Sutter Health in California, will present the clinical data abstract, “Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors.” The study explores a simplified method for measuring intra-arterial pressure during procedures that use the TAMP (Trans-Arterial Micro-Perfusion) therapy platform enabled by RenovoCath catheter, a double-balloon drug-delivery device, and how these measurements along with other variables can play a role in optimizing targeted delivery of chemotherapy in difficult-to-treat tumors. Illustration of RenovoCath delivering chemotherapy to tumor site via peripheral vascular system “This translational study not only aims to validate a practical, real-time method for intra-arterial pressure monitoring during TAMP procedures using RenovoCath, but also may reinforce the potential for individualized, optimized drug-delivery with our proprietary technology,” said Dr. Ramtin Agah, RenovoRx’s Chairman and Chief Medical Officer and co-author of the study. “We are excited to present the full data with Dr. Laing at the SIO 2026 Meeting as we continue to demonstrate the potential benefits of our therapy platform to the marketplace.” Abstract Details:Presentation Date & Time: Friday, February 6, 2026, at 5:45-6:00 PM ETTitle: Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro Perfusion to Optimize Drug Delivery in Solid TumorsLocation: ePoster CorridorAbstract Number: 303 Session Title: Science and Sips ePoster ReceptionAuthors: Christopher Laing, Robert Strasser, and Ramtin Agah About RenovoCathBased on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf. About RenovoRx, Inc.RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is in the early stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately $900,000 of revenues were generated from RenovoCath sales. Several customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner. RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The combination product candidate (IAG), which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X. Cautionary Note Regarding Forward-Looking StatementsThis press release and statements of the Company’s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated benefits to the Company of the clinical study abstract described herein, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law. Contact:KCSA Strategic CommunicationsValter Pinto or Jack PerkinsT:212-896-1254RenovoRx@KCSA.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b55e00e6-3f1f-4454-901a-ffbfd3afc4be

Phase 3ASCOOrphan Drug

27 Jan 2026

·www.fiercebiotech.com

Lisata reclaims China rights to solid tumor candidate ahead of acquisition

Qilu is still responsible for finishing a phase 2 study that is testing the candidate in patients with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma.\n Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead solid tumor candidate from Qilu Pharmaceutical.By bringing home certepetide, a cyclic peptide in midstage development for pancreatic ductal adenocarcinoma, Lisata shareholders are one step closer to snagging an extra $2 per share on top of the $4 per share that Kuva is paying for the New Jersey-based biotech. To finalize that pay bump, Kuva next needs to submit certepetide for approval in any country.Qilu originally licensed certepetide in mainland China, Hong Kong, Macau and Taiwan in February 2021 from Cend Therapeutics, which later became Lisata through a merger with Caladrius Biosciences in 2022. The decision to now tear up the deal was mutual, Lisata said in a Jan. 27 release.“We appreciate the collaboration and the work performed by Qilu with certepetide over the past few years,” Lisata President and CEO David Mazzo, Ph.D., said in the release. “As a result of this mutual termination, Lisata regains the full, exclusive rights to certepetide in the Greater China region.” Qilu is still responsible for finishing a phase 2 study that is testing the candidate in combination with the chemotherapy regimen gemcitabine/nab-paclitaxel in patients with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, according to the release.Kuva announced that it is acquiring Lisata on Jan. 21, after extensive prior experience with certepetide through a November 2024 pact to use the molecule with its own NanoMark platform to craft a new class of magnetic resonance tumor-detecting imaging agents.The mutually shredded deal comes on the same day Qilu inked another, offering up to $120 million to Insilico Medicine for artificial intelligence aid in developing new cardiometabolic disease candidates. Insilico will use its Pharma.AI platform to design small molecules for as-of-yet undisclosed targets, after which Jinan, China-based Qilu will take over further development.

AcquisitionPhase 2Drug ApprovalLicense out/inPhase 1

26 Jan 2026

·www.biospace.com

Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study

LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in combination with checkpoint inhibitor therapy in up to 24 patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC). The study is an investigator-led initiative in collaboration with Dr. Dan Fang at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York. "Building on the exciting clinical results generated in patients with solid tumors and strong preclinical data, we look forward to providing nadunolimab for evaluation in this new patient group. We are excited that a high-pro like the Tisch Cancer Institute views nadunolimab as a novel and promising therapy and are looking forward to offering patients this treatment option" said Hilde Steineger, CEO of Cantargia. " Microsatellite stable colorectal cancer remains one of the most challenging solid tumors to treat with immunotherapy ," said Dr. Dan Fang, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. " The scientific rationale for using a novel IL1RAP-targeting approach with nadunolimab is compelling, and we look forward to generating translational insights that could inform future immunotherapy strategies ." Nadunolimab has been investigated by Cantargia in approximately 300 patients with solid tumor indications and has shown signals of clinical activity in pancreatic cancer and non-small cell lung carcinoma. Researchers at the Tisch Cancer Institute have a long-standing interest in developing new therapies for the treatment of CRC and have performed preclinical work strongly implicating IL-1 signaling in immune suppressive and treatment resistant pathways in this disease. The new phase 1b/2a investigator-initiated trial will be conducted at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York. The study ( NCT07281716 ), led by principal investigator Dr. Dan Feng, is designed to investigate nadunolimab in combination with an anti-PD-1 inhibitor in up to 24 patients with MSS CRC. In addition to investigating anticancer effects, the study will include a comprehensive biomarker assessment package. For further information, please contact Hilde Steineger, CEO Telephone: +46 (0)46-275 62 60 E-mail: info@cantargia.com About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . About nadunolimab (CAN04) Nadunolimab is an antibody that binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab has been investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316 , evaluated nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Intriguing efficacy was observed in a small group of non-squamous NSCLC patients post PD(L)-1 therapy. Attachments Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study SOURCE: Cantargia View the original press release on ACCESS Newswire

ImmunotherapyAcquisitionClinical Study

100 Deals associated with Gemcitabine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01155	Gemcitabine Hydrochloride	L01BC05	DB00441

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	United States	Janssen Biotech, Inc.	09 Sep 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Australia	Sandoz Pty Ltd.	02 Dec 2008
Locally Advanced Pancreatic Adenocarcinoma	Australia	Sandoz Pty Ltd.	02 Dec 2008
metastatic non-small cell lung cancer	Australia	Sandoz Pty Ltd.	02 Dec 2008
Pancreatic adenocarcinoma metastatic	Australia	Sandoz Pty Ltd.	02 Dec 2008
Recurrent ovarian cancer	Australia	Sandoz Pty Ltd.	02 Dec 2008
Transitional Cell Carcinoma	Japan	Eli Lilly & Co.	25 Nov 2008
Bladder Cancer	Brazil	Libbs Farmacêutica Ltda.	26 May 2008
Biliary Tract Neoplasms	Japan	Eli Lilly & Co.	31 Aug 2001
Lymphoma	Japan	Eli Lilly & Co.	31 Aug 2001
Ovarian Cancer	Japan	Eli Lilly & Co.	31 Aug 2001
Breast Cancer	United States	Eli Lilly & Co.	15 May 1996
Metastatic breast cancer	United States	Eli Lilly & Co.	15 May 1996
Non-Small Cell Lung Cancer	United States	Eli Lilly & Co.	15 May 1996
Pancreatic adenocarcinoma	United States	Eli Lilly & Co.	15 May 1996
Pancreatic Cancer	United States	Eli Lilly & Co.	15 May 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced biliary tract cancer	Phase 3	Taiwan Province	InnoPharmax, Inc.	01 Jul 2025
Recurrent Bladder Cancer	Phase 3	United States	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	China	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	Japan	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	Argentina	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	Belgium	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	Brazil	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	France	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	Germany	Janssen Research & Development LLC	09 Apr 2024
Recurrent Bladder Cancer	Phase 3	Italy	Janssen Research & Development LLC	09 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04524702 (CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Advanced Pancreatic Adenocarcinoma	10	Hydroxychloroquine+Nab-paclitaxel+Gemcitabine+Paricalcitol	xgesbuouim = entgfwhnjq xbdqvlywbs (zuybjvefrt, fskueacuyc - jinttoqjed) View more	-	23 Jan 2026
NCT03377491 (PANOVA-3, CTgov)	Phase 3	Pancreatic Adenoma \| Locally Advanced Pancreatic Adenocarcinoma	571	Nab-paclitaxel+Gemcitabine (TTFields + Standard of Care)	vngvwqsxww(mpyvknrjrz) = ovrifzvhlo gehpmdiaij (canchymefi, ebgzbkjvcl - eakseiotco) View more	-	21 Jan 2026
				Nab-paclitaxel+Gemcitabine (Standard of Care)	vngvwqsxww(mpyvknrjrz) = lcvxqxrtss gehpmdiaij (canchymefi, ntpptymzud - ksowttpxjk) View more
NCT03943667 (GEMPAX, CTgov)	Phase 3	Pancreatic adenocarcinoma metastatic \| Metastatic Pancreatic Ductal Adenocarcinoma	211	Paclitaxel+Gemcitabine (GEMPAX)	evjmknxfes(tfqhnjwsgl) = gboxkwuiho fgsjfhliry (lzperpybvw, ffqxexxzvn - gxchfmnmix) View more	-	15 Jan 2026
				Gemcitabine (Control)	evjmknxfes(tfqhnjwsgl) = bqzqeorwxd fgsjfhliry (lzperpybvw, jgtvpohcqx - uvbgnutbnv) View more
NCT04539808 (NeoOPTIMIZE, CTgov)	Phase 2	Pancreatic adenocarcinoma \| Pancreatic Ductal Adenocarcinoma	42	mFOLFIRINOX+nab-paclitaxel+leucovorin calcium+gemcitabine hydrochloride+potassium+losartan+Oxaliplatin+irinotecan hydrochloride+capecitabine+fluorouracil	idexlmowfu = qmnidcuknu dbrpusjbor (kqygxrlncy, nduwrigcqz - fbvvltscka) View more	-	14 Jan 2026
ASCO_GI2026	Not Applicable	Advanced biliary tract cancer First line	172	Gemcitabine-cisplatin-durvalumab (GCD) (low-risk)	mhjnoynikg(jwpmeeubnj) = Magic-D achieved AUCs of 0.755 and 0.749 for 6- and 12- months survival prediction, respectively, outperforming NLR and other baseline factors. yerqnlurht (bzqhmeyljp )	Positive	08 Jan 2026
				Gemcitabine-cisplatin-durvalumab (GCD) (intermediate-risk)
ASCO_GI2026	Not Applicable	Biliary Tract Neoplasms First line	148	gemcitabine + cisplatin + immune checkpoint inhibitor	pggmdfstyo(dqfctynxhh) = wsaymykwxz vcyqesktos (htiyhrrorg, 10.6 - 16.4) View more	Positive	08 Jan 2026
				gemcitabine + cisplatin + S-1	pggmdfstyo(dqfctynxhh) = akmbcrgtaf vcyqesktos (htiyhrrorg, 8.5 - 13.5) View more
ASCO_GI2026	Not Applicable	Pancreatic adenocarcinoma metastatic First line	6,279	FOLFIRINOX	deabjmxjha(etbyknqooi) = wfsrinjweg pnerbthmsz (dlckwokeau, 10.2 - 12.1)	Negative	08 Jan 2026
				Gem-Nab	deabjmxjha(etbyknqooi) = hqcyknbnrr pnerbthmsz (dlckwokeau, 8.0 - 9.4)
NCT03678883 (1801 Part 3B, ASCO_GI2026)	Phase 2	Metastatic Pancreatic Cancer First line KRAS \| TP53 \| CDKN2A	170	Elraglusib/Gemcitabine/nab-paclitaxel	syzzicpowb(klgxkrqyuf) = KRAS and TP53 gene mutations were associated with worse overall survival (OS) in patients treated with elraglusib/GnP (p<0.05) but not in GnP-treated patients. gctzpacnyt (ltkxdxeqjk )	Positive	08 Jan 2026
				Gemcitabine/nab-paclitaxel
NCT04203160 (BilT-04, CTgov)	Phase 1/2	Unresectable Biliary Tract Carcinoma	75	Gemcitabine+cisplatin	lbiyuryaev = gtayuyitjj ayotqbndnj (wdiiozoiln, phkgalopdn - vmhzcpiorw) View more	-	31 Dec 2025
NCT03618550 (ASH2025)	Phase 2	Refractory Hodgkin Lymphoma Second line	39	Pembrolizumab 200mg IVVinorelbine 20mg/m² IV + Pembrolizumab 200mg IVVinorelbine 20mg/m²m² IV + Pembrolizumab 200mg IVVinorelbine 20mg/m² + Pembrolizumab 200mg IVVinorelbine 20mg/m²in 15mg/m² IV	tmsgtaucrn(abmhweyhwx) = lripxsbele cfeuhegjrn (mwifyvfdzi ) View more	Positive	06 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis